Marshall Wace LLP Has $752,000 Stake in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Marshall Wace LLP increased its stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) by 175.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 54,077 shares of the company's stock after buying an additional 34,463 shares during the quarter. Marshall Wace LLP owned about 0.11% of Tyra Biosciences worth $752,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the company. KLP Kapitalforvaltning AS acquired a new position in shares of Tyra Biosciences in the fourth quarter worth about $31,000. US Bancorp DE purchased a new stake in shares of Tyra Biosciences during the 4th quarter valued at approximately $50,000. Wells Fargo & Company MN lifted its stake in shares of Tyra Biosciences by 51.7% in the 4th quarter. Wells Fargo & Company MN now owns 9,493 shares of the company's stock valued at $132,000 after purchasing an additional 3,236 shares during the last quarter. Russell Investments Group Ltd. increased its position in shares of Tyra Biosciences by 130,587.5% during the fourth quarter. Russell Investments Group Ltd. now owns 10,455 shares of the company's stock valued at $145,000 after acquiring an additional 10,447 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in Tyra Biosciences in the fourth quarter valued at approximately $149,000. 84.14% of the stock is currently owned by hedge funds and other institutional investors.

Tyra Biosciences Trading Down 8.7 %

Tyra Biosciences stock traded down $0.87 during trading hours on Wednesday, reaching $9.13. 582,218 shares of the company were exchanged, compared to its average volume of 257,360. The stock has a 50-day moving average of $9.68 and a 200 day moving average of $13.56. The firm has a market cap of $484.71 million, a price-to-earnings ratio of -5.67 and a beta of 1.17. Tyra Biosciences, Inc. has a 12 month low of $6.42 and a 12 month high of $29.60.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.43) EPS for the quarter, topping analysts' consensus estimates of ($0.48) by $0.05. As a group, research analysts forecast that Tyra Biosciences, Inc. will post -1.57 EPS for the current year.

Wall Street Analyst Weigh In

TYRA has been the subject of a number of research analyst reports. UBS Group initiated coverage on Tyra Biosciences in a research report on Tuesday, January 7th. They issued a "buy" rating and a $28.00 target price for the company. Wedbush reaffirmed an "outperform" rating and set a $30.00 price target on shares of Tyra Biosciences in a research note on Friday, March 28th. Finally, HC Wainwright reiterated a "buy" rating and set a $30.00 price objective on shares of Tyra Biosciences in a research note on Monday, March 31st. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $30.83.

Tyra Biosciences Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.